Back to Search Start Over

Genetics of HLA Peptide Presentation and Impact on Outcomes in HLA-Matched Allogeneic Hematopoietic Cell Transplantation.

Authors :
Story, Charlotte McIlwaine
Story, Charlotte McIlwaine
Source :
Transplantation and cellular therapy; vol 27, iss 7, 591-599; 2666-6375
Publication Year :
2021

Abstract

Minor histocompatibility antigens (mHAs), recipient-derived peptide epitopes presented on the cell surface, are known to mediate graft-versus-host disease (GVHD); however, there are no current methods to associate mHA features with GVHD risk. This deficiency is due in part to the lack of technological means to accurately predict, let alone confirm, the tremendous number of potential mHAs in each individual transplant. Previous studies have shown that different HLA molecules present varying fractions of candidate peptide epitopes; however, the genetic "distance" between HLA-matched donors and recipients is relatively constrained. From these 2 observations, it is possible that the HLA type for a donor-recipient pair (DRP) would provide a surrogate measurement of the number of predicted mHAs, which could be related to GVHD risk. Because different HLA molecules present variable numbers of peptide antigens, a predicted cumulative peptide-binding efficiency can be calculated for individual DRP based on the pair's HLA type. The purpose of this study was to test whether cumulative peptide-binding efficiency is associated with the risk of acute GVHD (aGVHD) or relapse. In this retrospective Center for International Blood and Marrow Transplant Research study, a total of 3242 HLA-matched DRPs were analyzed for predicted cumulative peptide-binding efficiency using their HLA types and were divided into tertiles based on their scores. Univariable and multivariable analyses was performed to test for associations between cumulative peptide-binding efficiency for DRPs, divided into the HLA-matched related donor (MRD) and HLA-matched unrelated donor (MUD) cohorts, and the primary outcomes of aGVHD and relapse. Secondary outcomes investigated included overall survival, disease-free survival, and transplantation-related mortality. Using a computationally generated peptidome as a test dataset, the tested series of HLA class I displayed peptide-binding frequencies ranging from 0.1% to 3.

Details

Database :
OAIster
Journal :
Transplantation and cellular therapy; vol 27, iss 7, 591-599; 2666-6375
Notes :
Story, Charlotte McIlwaine, Wang, Tao, Bhatt, Vijaya Raj, Battiwalla, Minoo, Badawy, Sherif M, Kamoun, Malek, Gragert, Loren, Brown, Valerie, Baxter-Lowe, Lee Ann, Marsh, Steven GE, Gadalla, Shahinaz M, Schetelig, Johannes, Mytilineos, Joannis, Miklos, David, Waller, Edmund K, Kuxhausen, Michelle, Spellman, Stephen, Lee, Stephanie, Paczesny, Sophie, Lansford, Jefferson L, Vincent, Benjamin G, Riches, Marcie L, Armistead, Paul M, Center for International Blood and Marrow Transplant Research Immunobiology Working Committee
Publication Type :
Electronic Resource
Accession number :
edsoai.on1391592916
Document Type :
Electronic Resource